利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

6 条记录 (耗时 0.018 秒)

    Use of recombinant ganoderma immunoregulatory protein (rLZ-8) in preparation of drug for treating melanoma
    2.
    发明申请
    Use of recombinant ganoderma immunoregulatory protein (rLZ-8) in preparation of drug for treating melanoma 审中-公开
    使用重组灵芝免疫调节蛋白（rLZ-8）制备治疗黑色素瘤的药物

    公开(公告)号：US20160129077A1

    公开(公告)日：2016-05-12

    申请号：US14907263

    申请日：2014-06-13

    申请人： Xitian Zhang ,  Fei Sun

    发明人： Xitian Zhang ,  Fei Sun ,  Chongyang Liang

    IPC分类号： A61K38/16

    CPC分类号： A61K38/16

    摘要： A use of recombinant ganoderma immunoregulatory protein (rLZ-8) in a preparation of a drug for treating melanoma is disclosed. By establishing experimental animal models of orthotopic tumors and metastatic tumors, an anti-tumor effect of the rLZ-8 is researched, which indicates that the rLZ-8 significantly inhibits a growth of the orthotopic tumors of the melanoma and a formation of metastases of the melanoma.

    摘要翻译： 公开了重组灵芝免疫调节蛋白（rLZ-8）在制备治疗黑素瘤药物中的应用。 通过建立原位肿瘤和转移性肿瘤的实验动物模型，研究了rLZ-8的抗肿瘤作用，表明rLZ-8显着抑制黑素瘤原位肿瘤的生长，形成转移瘤 黑色素瘤

    Methoxypolyethyleneglycol succinimidyl propionate modified recombinant Ganoderma Lucidum immunoregulatory protein, preparing method and application thereof
    3.
    发明申请
    Methoxypolyethyleneglycol succinimidyl propionate modified recombinant Ganoderma Lucidum immunoregulatory protein, preparing method and application thereof 审中-公开
    甲氧基聚乙二醇丙酸琥珀酰亚胺酯改性重组灵芝免疫调节蛋白，其制备方法及应用

    公开(公告)号：US20150329601A1

    公开(公告)日：2015-11-19

    申请号：US14814356

    申请日：2015-07-30

    申请人： Xitian Zhang ,  Fei Sun

    发明人： Xitian Zhang ,  Fei Sun ,  Chongyang Liang

    IPC分类号： C07K14/37

    CPC分类号： C07K14/37 ,  A61K38/00 ,  A61K38/16 ,  A61K47/60 ,  C07K14/375

    摘要： Methoxypolyethyleneglycol succinimidyl propionate modified recombinant Ganoderma Lucidum immunoregulatory protein, a preparing method and applications thereof are provided, including: the mPEG-SPA modified rLZ-8; the method for preparing the mPEG-SPA modified rLZ-8 comprising: feeding the rLZ-8 dimer and the mPEG-SPA with the molar ratio of 1:1-1:6 into a 0.1M phosphate buffer with pH 5.0-pH 8.0, and stirring by a magnetic stirrer at a room temperature for 1.0-2.5 h, purifying the product for obtaining a modification product with a purity of 98%; and applications of the mPEG-SPA modified rLZ-8 in preparation of medicine for treating leukopenia due to chemotherapy. Advantages are as follows: the method for preparing the mPEG-SPA modified rLZ-8 is simple, and the product is identical; a half-life of the mPEG-SPA modified rLZ-8 is significantly longer than the half-life of unmodified rLZ-8 (illustrated in the FIG. 2); a minimum effective dosage and time for treating leucopenia are also improved.

    摘要翻译： 提供了甲氧基聚乙二醇琥珀酰亚胺基丙酸酯改性重组灵芝免疫调节蛋白，其制备方法及应用，包括：mPEG-SPA修饰的rLZ-8; 制备mPEG-SPA修饰的rLZ-8的方法包括：将rLZ-8二聚体和mPEG-SPA以1:1-1:6的摩尔比进料到pH 5.0-pH 8.0的0.1M磷酸盐缓冲液中， 并用磁力搅拌器在室温下搅拌1.0-2.5小时，纯化产物，得到纯度为98％的改性产物; 以及mPEG-SPA修饰的rLZ-8在化疗药物治疗白细胞减少症药物中的应用。 优点如下：制备mPEG-SPA改性rLZ-8的方法简单，产品相同; mPEG-SPA修饰的rLZ-8的半衰期明显长于未修饰的rLZ-8（如图2所示）的半衰期; 治疗白细胞减少症的最小有效剂量和时间也得到改善。

    Application of recombinant immunoregulatory protein of ganoderma lucidum in preparation of drug for treating focal cerebral ischemia
    5.
    发明申请
    Application of recombinant immunoregulatory protein of ganoderma lucidum in preparation of drug for treating focal cerebral ischemia 审中-公开
    灵芝重组免疫调节蛋白在制备治疗局灶性脑缺血的药物中的应用

    公开(公告)号：US20160199439A1

    公开(公告)日：2016-07-14

    申请号：US14912914

    申请日：2014-06-13

    申请人： Xitian ZHANG ,  Fei SUN

    发明人： Xitian Zhang ,  Fei Sun ,  Chongyang Liang

    IPC分类号： A61K38/16

    CPC分类号： A61K38/168

    摘要： An application of a recombinant immunoregulatory protein of ganoderma lucidum (rLZ-8) expressed by Pichia pastoris in a preparation of a drug for treating focal cerebral ischemia is provided. The rLZ-8 is able to treat a neurological function injury, decrease a neurological severity score caused by a cerebral injury and decrease an ED-1 positive cell number, so as to decrease an inflammatory response and inhibit apoptosis.

    摘要翻译： 提供了由巴斯德毕赤酵母表达的灵芝重组免疫调节蛋白（rLZ-8）在制备治疗局灶性脑缺血的药物中的应用。 rLZ-8能够治疗神经功能损伤，降低脑损伤引起的神经系统严重程度评分，降低ED-1阳性细胞数，减少炎症反应，抑制细胞凋亡。